Corvus Pharmaceuticals, Inc.
CRVS
$13.33
-$0.60-4.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.63% | 49.94% | 6.90% | 4.18% | 31.08% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.08% | 49.94% | 50.73% | 45.72% | 72.87% |
| Operating Income | -88.08% | -49.94% | -50.73% | -45.72% | -72.87% |
| Income Before Tax | -124.54% | -190.12% | -1.72% | 74.74% | -87.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -124.54% | -190.12% | -1.72% | 74.74% | -87.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -124.54% | -190.12% | -1.72% | 74.74% | -87.66% |
| EBIT | -88.08% | -49.94% | -50.73% | -45.72% | -72.87% |
| EBITDA | -88.28% | -49.98% | -50.79% | -45.76% | -73.00% |
| EPS Basic | -89.11% | -172.22% | 16.20% | 79.66% | -43.98% |
| Normalized Basic EPS | -88.96% | -172.21% | 16.25% | 79.67% | -44.17% |
| EPS Diluted | -89.11% | -15.05% | 16.20% | 79.66% | -43.98% |
| Normalized Diluted EPS | -88.96% | -175.24% | 16.25% | 79.67% | -44.17% |
| Average Basic Shares Outstanding | 18.76% | 24.78% | 21.38% | 24.19% | 30.25% |
| Average Diluted Shares Outstanding | 18.76% | 19.75% | 21.38% | 24.19% | 30.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |